These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 22395256)
1. Pegloticase: a novel agent for treatment-refractory gout. Shannon JA; Cole SW Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Sundy JS; Ganson NJ; Kelly SJ; Scarlett EL; Rehrig CD; Huang W; Hershfield MS Arthritis Rheum; 2007 Mar; 56(3):1021-8. PubMed ID: 17328081 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852 [TBL] [Abstract][Full Text] [Related]
4. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z; Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure gout. Yue CS; Huang W; Alton M; Maroli AN; Waltrip RW; Wright D; Marco MD J Clin Pharmacol; 2008 Jun; 48(6):708-18. PubMed ID: 18420531 [TBL] [Abstract][Full Text] [Related]
6. Pegloticase, a polyethylene glycol conjugate of uricase for the potential intravenous treatment of gout. Biggers K; Scheinfeld N Curr Opin Investig Drugs; 2008 Apr; 9(4):422-9. PubMed ID: 18393109 [TBL] [Abstract][Full Text] [Related]
7. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy. Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679 [TBL] [Abstract][Full Text] [Related]
8. Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials. Strand V; Khanna D; Singh JA; Forsythe A; Edwards NL J Rheumatol; 2012 Jul; 39(7):1450-7. PubMed ID: 22660805 [TBL] [Abstract][Full Text] [Related]
9. Pegloticase and the patient with treatment-failure gout. Dave AJ; Kelly VM; Krishnan E Expert Rev Clin Pharmacol; 2012 Sep; 5(5):501-8. PubMed ID: 23121270 [TBL] [Abstract][Full Text] [Related]
11. Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Hershfield MS; Ganson NJ; Kelly SJ; Scarlett EL; Jaggers DA; Sundy JS Arthritis Res Ther; 2014 Mar; 16(2):R63. PubMed ID: 24602182 [TBL] [Abstract][Full Text] [Related]
12. Pegloticase: in treatment-refractory chronic gout. Lyseng-Williamson KA Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516 [TBL] [Abstract][Full Text] [Related]